West Australian Researchers Explore Aged Garlic for Endometriosis Pain Management
In a groundbreaking initiative, researchers from the Perron Institute and Curtin University in Western Australia are launching a study to investigate the potential of aged garlic extracts as an alternative pain treatment for endometriosis. This condition affects approximately one in seven women, often causing severe and debilitating pain due to tissue similar to the uterine lining growing outside the uterus.
Understanding the MMEND Study and Its Objectives
The Microvascular Modulation in Endometriosis (MMEND) study, conducted at the Curtin Medical Research Institute and Perron Institute, aims to determine whether specific extracts derived from aged garlic bulbs, along with certain amino acids, can produce anti-inflammatory effects in patients. By targeting inflammation, the research hopes to minimize the chronic pain associated with endometriosis.
Professor John Mamo, head of neurovascular and metabolic diseases at Perron Institute and Curtin University, explained the scientific rationale behind the trial. "We are hopeful this treatment could be effective because evidence suggests endometriosis is an inflammatory condition that may impair blood flow through capillary vessels," he said. The study will involve some participants receiving only one component, while others will get a combination, to identify the most effective treatment approach.
Inspiration from Migraine Research and Anecdotal Evidence
The trial was inspired by Professor Mamo's earlier research on migraine pain, which used a similar treatment. During that study, female participants with endometriosis reported anecdotal reductions in their endometrial pain. "From the first migraine trial we conducted, we had some of our female participants anecdotally telling us that their endometrial pain was feeling better," Professor Mamo recalled.
He emphasized the significance of this discovery, noting that endometriosis represents the second major pain burden for women after migraines. "We felt it incumbent upon us to try and explore whether this intervention approach might be useful in that context. If we can show that in combination, there is a therapeutic dose effect in reducing the two biggest pain burdens in women, well, that's an extraordinary outcome, and we want to get that out to the community as quickly as we possibly can," he added.
Potential Benefits and Clinical Trial Details
Clinical trial coordinator Emily Redwood, a dietitian and Curtin University PhD candidate, highlighted the potential advantages of the treatment. "If effective, this treatment could be more cost-effective and have fewer side effects than current medications for endometriosis," she stated. Redwood shared insights from her professional experience, saying, "Through my work as a dietitian, I've seen countless patients living with this debilitating pain, which significantly impacts career progression, social life, mental health, and overall wellbeing."
She further explained the limitations of existing treatments: "People with endometriosis often rely on painkillers or other medications daily, which have many side effects and may not be suitable for long-term use. If successful, this could provide an alternative option that is cost-effective and potentially lacks the severe side effects of current treatments." Redwood stressed the need for more research, noting, "There's only emerging evidence in this space, so we need more trials like what we're doing at Curtin and Perron to give health professionals the evidence to make recommendations."
Recruitment and Eligibility Criteria for the Trial
The MMEND study is currently recruiting participants for a 56-week trial. Eligibility criteria include:
- A confirmed diagnosis of endometriosis
- Residency in Perth, Western Australia
- Age between 18 and 45 years
- Not currently pregnant, breastfeeding, or planning a pregnancy within the next 56 weeks
Individuals interested in participating are encouraged to visit the study's official website or contact the research team via email for more information and enrollment details.
